Niagen Bioscience
NAGE
58 hedge funds and large institutions have $42.2M invested in Niagen Bioscience in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
29% more capital invested
Capital invested by funds: $32.7M → $42.2M (+$9.45M)
0.89% more ownership
Funds ownership: 17.32% → 18.21% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less call options, than puts
Call options by funds: $95K | Put options by funds: $98K
5% less funds holding
Funds holding: 61 → 58 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$597K |
| 2 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$596K |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$283K |
| 4 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
+$234K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
-$172K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$154K |
| 3 |
Morgan Stanley
New York
|
-$87.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$72K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$53.3K |
NAGE Hedge Fund Activity: Q1 2019 in Review
58 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2019, worth a combined $42.2M — up 29% from $32.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NAGE and 8 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $597K. The largest seller was Oppenheimer & Co, exiting entirely with an estimated $172K sold.
- 58 institutional investors held Niagen Bioscience (NAGE) as of Q1 2019, down from 61 in Q4 2018.
- Funds reported $42.2M of Niagen Bioscience stock for Q1 2019, up 29% quarter-over-quarter.
- 8 funds opened new Niagen Bioscience positions in Q1 2019 and 11 closed out, a net change of -3 holders.
- The largest Niagen Bioscience buyer in Q1 2019 was Vanguard Group, an estimated $597K added.
- The largest Niagen Bioscience seller in Q1 2019 was Oppenheimer & Co, an estimated $172K sold.
Based on aggregated 13F filings for Q1 2019.